Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients.

de Noronha e Menezes NM, Lima R, Moreira A, Varela P, Barroso A, Baptista A, Parente B.

Eur J Dermatol. 2009 May-Jun;19(3):248-51. doi: 10.1684/ejd.2009.0650. Epub 2009 Mar 3.

PMID:
19258241
2.

Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.

Eames T, Landthaler M, Karrer S.

Eur J Dermatol. 2007 Nov-Dec;17(6):552-3. Epub 2007 Oct 19. No abstract available.

PMID:
17951151
3.

Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions.

Amitay-Laish I, David M, Stemmer SM.

Oncologist. 2010;15(9):1002-8. doi: 10.1634/theoncologist.2010-0063. Epub 2010 Aug 13.

4.

[Cutaneous side effects of EGFR inhibitors--appearance and management].

Wollenberg A, Kroth J, Hauschild A, Dirschka T.

Dtsch Med Wochenschr. 2010 Jan;135(4):149-54. doi: 10.1055/s-0029-1244831. Epub 2010 Jan 25. Review. German.

PMID:
20101558
5.

Erlotinib-induced pustular eruption.

Cusano F, Ferrara G, Barletta E, Ingordo V.

G Ital Dermatol Venereol. 2009 Feb;144(1):93-6.

PMID:
19218915
6.

Adverse cutaneous reactions to epidermal growth factor receptor inhibitors: a study of 14 patients.

Santiago F, Gonçalo M, Reis JP, Figueiredo A.

An Bras Dermatol. 2011 May-Jun;86(3):483-90. English, Portuguese.

7.

Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.

Ocvirk J, Cencelj S.

J Eur Acad Dermatol Venereol. 2010 Apr;24(4):453-9. doi: 10.1111/j.1468-3083.2009.03446.x. Epub 2009 Sep 27.

PMID:
19793151
9.

Acneiform reaction to erlotinib.

Schalock PC, Zug KA.

Dermatitis. 2007 Dec;18(4):230-1.

PMID:
18021605
10.

Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients.

Roé E, García Muret MP, Marcuello E, Capdevila J, Pallarés C, Alomar A.

J Am Acad Dermatol. 2006 Sep;55(3):429-37. Epub 2006 Jul 13.

PMID:
16908348
11.

[Contribution to acneiform eruptions by epidermal growth factor receptor inhibitors].

Bodet D, Bartralot R, Mollet J, Heras C, García-Patos V.

Actas Dermosifiliogr. 2006 Mar;97(2):148-9. Spanish. No abstract available.

PMID:
16595122
12.

Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.

Kiyohara Y, Yamazaki N, Kishi A.

J Am Acad Dermatol. 2013 Sep;69(3):463-72. doi: 10.1016/j.jaad.2013.02.025. Epub 2013 Apr 17. Review.

13.

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.

Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.

Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.

14.
15.

Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.

Weickhardt AJ, Price TJ, Chong G, Gebski V, Pavlakis N, Johns TG, Azad A, Skrinos E, Fluck K, Dobrovic A, Salemi R, Scott AM, Mariadason JM, Tebbutt NC.

J Clin Oncol. 2012 May 1;30(13):1505-12. doi: 10.1200/JCO.2011.38.6599. Epub 2012 Mar 12.

16.

Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.

Johnson JR, Cohen M, Sridhara R, Chen YF, Williams GM, Duan J, Gobburu J, Booth B, Benson K, Leighton J, Hsieh LS, Chidambaram N, Zimmerman P, Pazdur R.

Clin Cancer Res. 2005 Sep 15;11(18):6414-21.

17.

Cetuximab-induced cutaneous toxicity.

Tomková H, Kohoutek M, Zábojníková M, Pospísková M, Ostrízková L, Gharibyar M.

J Eur Acad Dermatol Venereol. 2010 Jun;24(6):692-6. doi: 10.1111/j.1468-3083.2009.03490.x. Epub 2009 Nov 18.

PMID:
19925598
18.

Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption.

Scope A, Agero AL, Dusza SW, Myskowski PL, Lieb JA, Saltz L, Kemeny NE, Halpern AC.

J Clin Oncol. 2007 Dec 1;25(34):5390-6.

19.

Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.

Martinelli E, Troiani T, Morgillo F, Rodolico G, Vitagliano D, Morelli MP, Tuccillo C, Vecchione L, Capasso A, Orditura M, De Vita F, Eckhardt SG, Santoro M, Berrino L, Ciardiello F.

Clin Cancer Res. 2010 Oct 15;16(20):4990-5001. doi: 10.1158/1078-0432.CCR-10-0923. Epub 2010 Sep 1.

20.

Acneiform eruption induced by cetuximab.

Cotena C, Gisondi P, Colato C, Girolomoni G.

Acta Dermatovenerol Croat. 2007;15(4):246-8.

PMID:
18093454
Items per page

Supplemental Content

Write to the Help Desk